Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

Stock analysts at HC Wainwright reduced their FY2029 earnings estimates for Oncolytics Biotech in a research note issued on ...

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized ...

Oncolytics Biotech Inc. (ONCY) reported its Q4 2024 financial results, presenting a net loss of $8 million, compared to $3.9 million in the same quarter of the previous year. According to ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic ...

Oncolytics Biotech has a treatment in development for breast, pancreatic, and anal cancer. Pharmaceutical Executive spoke with chief medical officer Thomas C. Heineman, MD, PhD, and vice president of ...